Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) and Scilex (NASDAQ:SCLX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
Institutional and Insider Ownership
9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Iterum Therapeutics and Scilex”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Iterum Therapeutics | $390,000.00 | 4.10 | -$24.77 million | ($0.75) | -0.04 |
| Scilex | $30.25 million | 1.25 | -$358.73 million | ($49.70) | -0.09 |
Iterum Therapeutics has higher earnings, but lower revenue than Scilex. Scilex is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Iterum Therapeutics and Scilex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Iterum Therapeutics | N/A | N/A | -65.54% |
| Scilex | -1,414.57% | N/A | -147.00% |
Analyst Ratings
This is a summary of current ratings and price targets for Iterum Therapeutics and Scilex, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Iterum Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Scilex | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500. Comparatively, Scilex has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
Summary
Iterum Therapeutics beats Scilex on 8 of the 11 factors compared between the two stocks.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
About Scilex
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
